Palo Alto, California, United States The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Palo Alto.
Among the most popular portfolio startups of the fund, we may highlight Novexel, Diatos, REGiMMUNE Corporation. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Computer. For fund there is no match between the location of its establishment and the land of its numerous investments - France.
The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2009. The important activity for fund was in 2007. Opposing the other organizations, this NIF SMBC Ventures works on 11 percentage points more the average amount of lead investments. The fund is generally included in less than 2 deals every year.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the NIF SMBC Ventures, startups are often financed by Sofinnova Partners, Japan Asia Investment, Crosspoint Venture Partners. The meaningful sponsors for the fund in investment in the same round are Japan Asia Investment, Yasuda Enterprise Development, Sofinnova Partners. In the next rounds fund is usually obtained by Japan Asia Investment, Yasuda Enterprise Development, SMBC Venture Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Broadleaf | Japan, Tokyo |
| China Summit Capital | China, Shanghai |
| Clover Wolf and Clover Alpha | - |
| Cyrus Capital Partners | New York, New York, United States |
| Dada Entertainment | New York, New York, United States |
| Finn Evdemon Capital Partners | Central, Central Region, Singapore |
| FRCI | Mauritius, Phoenix, Plaines Wilhems |
| Grovest | Gauteng, Johannesburg, South Africa |
| Hearst Television Inc. | New York, New York, United States |
| Invia.cz | Czechia, Prague, Prague |
| Jianpu Technology | Beijing, Beijing, China |
| Killik & Co | England, London, United Kingdom |
| Lumikai | Delhi, India, New Delhi |
| Mimecast | - |
| Nissei Capital | Chiyoda, Japan |
| Robeco Private Equity | - |
| Struck Capital | California, Santa Monica, United States |
| Symphony International Holdings | China, Hong Kong, Hong Kong Island |
| United News of India | Delhi, India, New Delhi |
| Weipinhui | China, Guangdong, Guangzhou |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
REGiMMUNE Corporation | $8M | 06 May 2008 | Chiyoda | ||
REGiMMUNE Corporation | $6M | 01 Feb 2008 | Chiyoda | ||
REGiMMUNE Corporation | $4M | 21 Feb 2007 | Chiyoda, Japan | ||
Novexel | $65M | 25 Jan 2007 | France, Ile-de-France, France | ||
Digital Media Group | 08 Jan 2007 | New South Wales | |||
Abionyx Pharma | $53M | 12 Nov 2006 | Balma, Midi-Pyrenees, France | ||
REGiMMUNE Corporation | $1M | 15 Aug 2006 | Chiyoda | ||
Abionyx Pharma | $30M | 22 Aug 2005 | Balma, Midi-Pyrenees, France | ||
Innate Pharma | $17M | 01 Sep 2004 | Marseille, Provence-Alpes-Côte d'Azur, France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
REGiMMUNE Corporation | $8M | 06 May 2008 | Chiyoda | ||
REGiMMUNE Corporation | $6M | 01 Feb 2008 | Chiyoda | ||
REGiMMUNE Corporation | $4M | 21 Feb 2007 | Chiyoda, Japan | ||
Novexel | $65M | 25 Jan 2007 | France, Ile-de-France, France | ||
Digital Media Group | 08 Jan 2007 | New South Wales | |||
Abionyx Pharma | $53M | 12 Nov 2006 | Balma, Midi-Pyrenees, France | ||
REGiMMUNE Corporation | $1M | 15 Aug 2006 | Chiyoda | ||
Abionyx Pharma | $30M | 22 Aug 2005 | Balma, Midi-Pyrenees, France | ||
Innate Pharma | $17M | 01 Sep 2004 | Marseille, Provence-Alpes-Côte d'Azur, France |
